Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
601 · 3 trials · 2 indications
Assessed with Early treatment diabetic retinopathy study (ETDRS) visual acuity testing charts.
Assessed with ETDRS visual acuity testing charts.
| Arm | Type | Description |
|---|---|---|
| 601 1.25mg | EXPERIMENTAL | loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses |
| ranibizumab 0.5mg | ACTIVE_COMPARATOR | loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses |
| Ranibizuman 0.5 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 601 1.25mg | DRUG | loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses |
| ranibizumab 0.5mg | DRUG | loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses |
| Ranibizuman 0.5 mg | DRUG | Solution for injection (intravitreal use) |
Inclusion Criteria: * Sign informed consent form and willing to be followed up at the time specified in the trial * Male or Female, at least 18 years of age * The study eye must meet the following criteria：Diagnosed with macular edema secondary to Branch retinal vein occlusion (BRVO) or Hemi-retina...
601 is an investigational small molecule being developed for the treatment of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), which are eye conditions that can cause vision loss. It is administered as an ophthalmic treatment and is currently in clinical development.
601 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the stock market under the ticker symbol SBFM. The company is conducting clinical trials for this drug in patients with retinal vein occlusion.
601 is in Phase 3 clinical development. It has completed Phase 2 and Phase 3 trials, with the most advanced study being a Phase 3 trial comparing 601 to ranibizumab in patients with vision loss due to branch retinal vein occlusion.
601 is a small molecule designed to treat retinal vein occlusion, a condition where a vein in the retina becomes blocked, leading to vision problems. Its specific molecular target has not been disclosed, but it is being studied as a treatment for this eye condition.
601 has been studied in two completed Phase 2 trials (NCT04667897 and NCT04667910) and one completed Phase 3 trial (NCT05520177). These trials compared 601 to ranibizumab in patients with branch retinal vein occlusion and central retinal vein occlusion.
601 is not FDA approved. It is an investigational drug currently in clinical development, with completed Phase 2 and Phase 3 trials. It has not yet received regulatory approval for marketing in the United States or other countries.